Condition
Distributive Shock
Total Trials
6
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
2 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Terminated2
Unknown2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04904562Phase 4TerminatedPrimary
Angiotensin II for Distributive Shock
NCT03407287Terminated
Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status
NCT03623529Phase 2Unknown
A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
NCT03431077Phase 2Completed
A Study of LJPC-501 in Pediatric Patients With Hypotension
NCT02338843Phase 3Completed
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
NCT03245528Unknown
Expanded Access for LJPC-501
Showing all 6 trials